Pharmacotherapy of Thromboembolism
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 25 February 2025 | Viewed by 7821
Special Issue Editors
2. Division of acute and interventional cardiology, Department of Cardiology and Angiology II, Mid-Slovakian Institiute of Heart and Vessel Diseases (SÚSCCH) in Banská Bystrica, Slovakia
Interests: antithrombotic therapy; direct oral anticoagulants; laboratory monitoring of antithrombotic therapy; factors influencing the efficacy of antithrombotic therapy; stent thrombosis
Interests: direct oral anticoagulants; gastroprotection and antithrombotic therapy; bleeding on antithrombotic agents; factors influencing the efficacy of antithrombotic therapy
Special Issue Information
Dear Colleagues,
Thromboembolism (arterial and venous) is still an emergency clinical situation with high mortality and postevent morbidity. Moreover, the number of patients at risk for antithrombotic therapy-related complications who require long-term anticoagulation is increasing. Long-term antithrombotic therapy in patients with chronic diseases, elderly and frail patients, patients with cancer-related thromboembolism, or patients with the need for chronic anticoagulation who undergo vascular interventions could be problematic. Currently, the long-term pharmacotherapy of thromboembolism remains challenging and needs further research.
In addition, with the growing complexity of interventional procedures, the risk of future thrombotic complications increases. Antithrombotic therapy is crucial to prevent or to treat these complications. The role of modern antiplatelet agents in the prevention of thrombotic target lesion failure is being questioned and widely studied, but still with conflicting results, not allowing any final recommendations.
Finally, several novel antithrombotic agents, namely activated factor XI inhibitors, platelet glycoprotein VI antagonists, PAR4 antagonists, and PI3K inhibitors, are being either intensively studied, or introduced to phase II or III clinical testing. These novel agents could improve the efficacy and/or safety of long-term anticoagulation in future and require our attention.
This Special Issue has the aim to summarize the state-of-the-art drug discovery and drug design, and the latest findings in the field of long-term antithrombotic therapy, management of antithrombotic therapy in challenging clinical situations, and antithrombotic strategies in acute thrombotic complications during invasive vascular procedures. Original articles and reviews are welcomed for publication in this Special Issue.
Some of the questions that could tackle the Special Issue theme include, but are not limited to, the following:
- Activated factor XI inhibitors as an anti-thrombotica and anticoagulant agent in treatment of thromboembolism.
- Synthesis, biological evaluation and molecular modeling studies of different platelet glycoprotein VI antagonists.
- Small molecules in the field of antiplatelet agents with Protease activated receptor 4 (PAR4) antagonistic mechanism.
- Current progress of using PI3K inhibitors in therapy.
- Safety of long-term anticoagulant therapy use.
- Drug-drug interactions of anticoagulants with different therapeutics.
Dr. Matej Samoš
Dr. Tomáš Bolek
Prof. Dr. Marián Mokáň
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- activated factor XI inhibitors
- platelet glycoprotein VI antagonists
- PAR4 antagonists
- PI3K inhibitorslong-term anticoagulation
- antiplatelet therapy
- novel antithrombotic drugs
- anticoagulation-related bleeding
- post-vascular procedure-related thrombosis
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
